ArticleJAC-antimicrobial resistance2021
Emergence of non-susceptibility during persistent
Article in JAC-antimicrobial resistance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 3 citations in OpenAlex.
- Pseudomonas aeruginosa ExoU-associated virulence in HCT recipients and patients with hematologic malignancies.Blood advances · 2023Article
- Clinical and Epidemiological Characteristics of Persistent Bacteremia: A Decadal Observational Study.Pathogens (Basel, Switzerland) · 2023Article
- Long-Term Dominance of Carbapenem-Non-SusceptibleFrontiers in cellular and infection microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystematic studies pertaining to the emergence of resistance during therapy of
objectivesTo determine how frequently non-susceptibility emerges during therapy of PATIENTS AND
methods
resultsIn total, 96 BSI episodes among 86 HCT/HM patients were analysed. Eight persistent BSI episodes (8.3%) occurred in eight patients (9.3%). Repeat susceptibility testing was performed in seven (87.5%) of these episodes. Non-susceptibility to the treatment agent emerged in five (71.4%) episodes and to any antipseudomonal agent in seven (100%) episodes. The 21 day mortality rate associated with persistent BSI was 87.5% (seven of eight), and it was 80% (four of five) among persistent BSI episodes in which non-susceptibility to the treatment agent emerged on therapy. Non-susceptibility to any antipseudomonal agent during persistent BSI emerged significantly more frequently in HCT/HM patients compared with non-HCT/HM patients.
conclusionsNon-susceptibility emerges frequently during persistent
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.